Insilico Secures $2.5B AI Drug Discovery Partnership with SK Biopharm

AI drug discovery company Insilico has signed a heavily backloaded $2.5 billion deal with SK Biopharm to develop novel therapeutics using artificial intelligence. The structure emphasizes performance-based payments, indicating SK Biopharm's confidence in Insilico's AI platform while protecting the biotech's upfront investment.

Why it matters: This major partnership validates AI-driven drug discovery as a viable pathway for pharma companies and signals accelerating adoption of machine learning in early-stage drug development.